BR0113447A - Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica - Google Patents
Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêuticaInfo
- Publication number
- BR0113447A BR0113447A BR0113447-7A BR0113447A BR0113447A BR 0113447 A BR0113447 A BR 0113447A BR 0113447 A BR0113447 A BR 0113447A BR 0113447 A BR0113447 A BR 0113447A
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- present
- treating
- human
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Abstract
"MéTODO DE TRATAMENTO OU PREVENçãO DO CâNCER EM UM SER HUMANO, E, COMPOSIçãO FARMACêUTICA". A presente invenção está direcionada ao uso de oligómeros anti-sentido bc1-2 para tratar e prevenir distúrbios relacionados com bc1-2. Esses distúrbios incluem câncer, tumores, carcinomas e distúrbios relacionados a proliferação de células. Em uma modalidade da invenção, oligómero anti-sentido bc1-2 é administrado em doses altas. A presente invenção está também direcionada ao método para prevenir ou tratar distúrbios relacionados com bc1-2, em particular câncer, compreendendo administrar oligómero anti-sentido bc1-2 para períodos de tempo curtos. A presente invenção é ainda descrita para usar os oligómeros anti-sentido bc1-2 para aumentar a sensitividade de um paciente para terapêuticos de câncer. A presente invenção também refere-se a composições farmacêuticas compreendendo um ou mais oligómeros anti-sentido bc1-2, que podem compreender um ou mais agentes terapêuticos de câncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22797000P | 2000-08-25 | 2000-08-25 | |
US23700900P | 2000-09-29 | 2000-09-29 | |
US09/709,170 US7795232B1 (en) | 2000-08-25 | 2000-11-10 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
PCT/US2001/026414 WO2002017852A2 (en) | 2000-08-25 | 2001-08-23 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113447A true BR0113447A (pt) | 2003-07-08 |
Family
ID=27397795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113447-7A BR0113447A (pt) | 2000-08-25 | 2001-08-23 | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica |
Country Status (33)
Country | Link |
---|---|
US (2) | US7795232B1 (pt) |
EP (2) | EP1313514B1 (pt) |
JP (1) | JP2004507480A (pt) |
KR (1) | KR20030034153A (pt) |
CN (1) | CN1471408A (pt) |
AP (1) | AP2003002761A0 (pt) |
AT (1) | ATE432717T1 (pt) |
AU (2) | AU2001288373B2 (pt) |
BG (1) | BG107641A (pt) |
BR (1) | BR0113447A (pt) |
CA (1) | CA2419480A1 (pt) |
CY (1) | CY1109340T1 (pt) |
CZ (1) | CZ301582B6 (pt) |
DE (1) | DE60138892D1 (pt) |
DK (1) | DK1313514T3 (pt) |
DZ (1) | DZ3471A1 (pt) |
EA (1) | EA005424B1 (pt) |
EE (1) | EE200300074A (pt) |
ES (1) | ES2327904T3 (pt) |
GE (1) | GEP20063934B (pt) |
HK (1) | HK1056505A1 (pt) |
HR (1) | HRP20030102A2 (pt) |
HU (1) | HUP0303125A2 (pt) |
IL (1) | IL154409A0 (pt) |
MX (1) | MXPA03001575A (pt) |
NO (1) | NO20030858L (pt) |
OA (1) | OA12586A (pt) |
PL (1) | PL363050A1 (pt) |
PT (1) | PT1313514E (pt) |
SK (1) | SK3652003A3 (pt) |
UA (1) | UA77945C2 (pt) |
WO (1) | WO2002017852A2 (pt) |
YU (1) | YU13603A (pt) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
EP2258872B1 (en) | 2002-03-13 | 2013-08-14 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
US7256284B2 (en) | 2002-11-14 | 2007-08-14 | Genta Incorporated | Inhibitory oligonucleotides targeted to Bcl-2 |
CA2506066A1 (en) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
DE10258677A1 (de) * | 2002-12-13 | 2004-06-24 | Elez, Vera, Dr. | Kombinations-antisense-Oligonukleotid-Krebstherapie |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
PT1597391E (pt) | 2003-02-20 | 2008-12-19 | Genomic Health Inc | Utilização de arn intrónico para medir a expressão genética |
JP4505749B2 (ja) | 2003-05-30 | 2010-07-21 | 日本新薬株式会社 | Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物 |
CA3061769C (en) | 2003-06-24 | 2021-10-26 | Genomic Health, Inc. | Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer |
WO2005008213A2 (en) | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
KR20070000438A (ko) | 2003-12-23 | 2007-01-02 | 게노믹 헬쓰, 인코포레이티드 | 단편화 rna의 범용적 증폭 |
GB0406415D0 (en) * | 2004-03-22 | 2004-04-21 | Inst Of Cancer Res The | Materials and methods for treatment of cancer |
EP1737980A2 (en) | 2004-04-09 | 2007-01-03 | Fondazione IRCCS Istituto Nazionale dei Tumori | Gene expression markers for predicting response to chemotherapy |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
AU2013203202B2 (en) * | 2004-08-26 | 2017-02-16 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells |
JP4965447B2 (ja) | 2004-08-26 | 2012-07-04 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニセルを介した哺乳動物細胞への機能性核酸の送達 |
DK1815014T3 (da) | 2004-11-05 | 2012-06-18 | Genomic Health Inc | Molekylære indikatorer for brystcancerprognose og forudsigelse af behandlingsrespons |
JP5020088B2 (ja) | 2004-11-05 | 2012-09-05 | ジェノミック ヘルス, インコーポレイテッド | 遺伝子発現マーカーを使用する、化学療法に対する反応の予測 |
JP5122474B2 (ja) * | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
CN100368424C (zh) * | 2006-07-21 | 2008-02-13 | 福建金山生物制药股份有限公司 | 抑制肿瘤的反义核苷酸 |
US20080171718A1 (en) * | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
DE102007020554A1 (de) * | 2007-04-27 | 2008-10-30 | Henkel Ag & Co. Kgaa | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
WO2009071681A2 (en) * | 2007-12-07 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of bcl-2 |
JP2012509878A (ja) * | 2008-11-21 | 2012-04-26 | アイシス ファーマシューティカルズ, インコーポレーテッド | ドセタキセルおよびアンチセンスオリゴヌクレオチドを含む、抗腫瘍併用療法 |
IN2012DN00969A (pt) | 2009-07-30 | 2015-04-10 | Antisense Pharma Gmbh | |
EP2521785B1 (en) * | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2731377T3 (es) | 2015-07-07 | 2019-11-15 | Hoffmann La Roche | Politerapia con un conjugado anticuerpo anti-HER2-fármaco y un inhibidor de bcl-2 |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2021231486A1 (en) * | 2020-05-13 | 2021-11-18 | Unity Biotechnology, Inc. | Cancer treatment by senescence induction followed by a senolytic |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
EP0633934A1 (en) | 1992-04-02 | 1995-01-18 | Imperial Cancer Research Technology Limited | Modified cells and method of treatment |
CA2147663A1 (en) | 1992-10-21 | 1994-04-28 | Bruno Calabretta | Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer |
US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
US5783683A (en) * | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
-
2000
- 2000-11-10 US US09/709,170 patent/US7795232B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 UA UA2003032532A patent/UA77945C2/uk unknown
- 2001-08-23 EP EP01968097A patent/EP1313514B1/en not_active Expired - Lifetime
- 2001-08-23 CZ CZ20030848A patent/CZ301582B6/cs not_active IP Right Cessation
- 2001-08-23 AP APAP/P/2003/002761A patent/AP2003002761A0/en unknown
- 2001-08-23 PT PT01968097T patent/PT1313514E/pt unknown
- 2001-08-23 CN CNA018177107A patent/CN1471408A/zh active Pending
- 2001-08-23 YU YU13603A patent/YU13603A/sh unknown
- 2001-08-23 WO PCT/US2001/026414 patent/WO2002017852A2/en active IP Right Grant
- 2001-08-23 CA CA002419480A patent/CA2419480A1/en not_active Abandoned
- 2001-08-23 BR BR0113447-7A patent/BR0113447A/pt not_active IP Right Cessation
- 2001-08-23 IL IL15440901A patent/IL154409A0/xx unknown
- 2001-08-23 OA OA1200300058A patent/OA12586A/en unknown
- 2001-08-23 GE GE5129A patent/GEP20063934B/en unknown
- 2001-08-23 PL PL01363050A patent/PL363050A1/xx not_active IP Right Cessation
- 2001-08-23 HU HU0303125A patent/HUP0303125A2/hu unknown
- 2001-08-23 JP JP2002522827A patent/JP2004507480A/ja not_active Withdrawn
- 2001-08-23 AU AU2001288373A patent/AU2001288373B2/en not_active Ceased
- 2001-08-23 DZ DZ013471A patent/DZ3471A1/fr active
- 2001-08-23 EA EA200300294A patent/EA005424B1/ru not_active IP Right Cessation
- 2001-08-23 AU AU8837301A patent/AU8837301A/xx active Pending
- 2001-08-23 DK DK01968097T patent/DK1313514T3/da active
- 2001-08-23 AT AT01968097T patent/ATE432717T1/de active
- 2001-08-23 MX MXPA03001575A patent/MXPA03001575A/es active IP Right Grant
- 2001-08-23 SK SK365-2003A patent/SK3652003A3/sk unknown
- 2001-08-23 DE DE60138892T patent/DE60138892D1/de not_active Expired - Lifetime
- 2001-08-23 ES ES01968097T patent/ES2327904T3/es not_active Expired - Lifetime
- 2001-08-23 EP EP09007273A patent/EP2135623A1/en not_active Withdrawn
- 2001-08-23 EE EEP200300074A patent/EE200300074A/xx unknown
- 2001-08-23 KR KR10-2003-7002605A patent/KR20030034153A/ko active Search and Examination
-
2003
- 2003-02-13 HR HR20030102A patent/HRP20030102A2/hr not_active Application Discontinuation
- 2003-02-24 NO NO20030858A patent/NO20030858L/no unknown
- 2003-03-18 BG BG107641A patent/BG107641A/bg unknown
- 2003-11-28 HK HK03108693.0A patent/HK1056505A1/xx not_active IP Right Cessation
-
2009
- 2009-09-02 CY CY20091100919T patent/CY1109340T1/el unknown
-
2010
- 2010-04-02 US US12/753,285 patent/US20100216867A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113447A (pt) | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica | |
BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BR9715022A (pt) | Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
BR0309280A (pt) | Terapia de combinação para o tratamento de câncer | |
KR960703009A (ko) | 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용 | |
ES2162615T3 (es) | Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina. | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
ES2172654T3 (es) | Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe. | |
IL107109A0 (en) | Compounds for modifying drug resistance and pharmaceutical compositions containing the same | |
BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
BR0111207A (pt) | Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
BR0315573A (pt) | Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica | |
MX9708800A (es) | Compuestos biciclicos aromaticos. | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
DE69400353T2 (de) | Schlankmachende Zusammensetzung | |
NZ328874A (en) | Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders | |
MX9708803A (es) | Compuestos biaromaticos de propinilo o dienilo. | |
BR9809694A (pt) | Processo e composição para administração de taxanos oralmente a pacientes humanos | |
BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2164 DE 26/06/2012. |